-
Mashup Score: 2Association of RNF43 Genetic Alterations With BRAFV600E and MSIhigh in Colorectal Cancer - 2 month(s) ago
PURPOSE Recent studies have provided evidence for a predictive value of RNF43 genetic alterations (GAs) as biomarkers for targeted therapies in microsatellite-stable (MSS) colorectal cancer (CRC). These data have the potential to prioritize treatment strategies in patients with BRAFV600E-mutant CRC and help to identify a subgroup that is more likely to derive benefit versus those patients for whom alternative treatment approaches are needed. We were therefore interested in defining the precise frequency of BRAFV600E and RNF43 GAs and their respective overlap in a large cohort of patients with CRC. METHODS To address this question, we performed a retrospective analysis that included 52,969 patients diagnosed with CRC from the FoundationCORE database. RESULTS We observed a striking association of RNF43 GAs with MSI and tumor mutational burden status and BRAFV600E mutations. Overall, 23% of MSS patients with confirmed BRAFV600E mutation harbor an RNF43 GA—which accounts for 1.1% of all pa
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK - 2 month(s) ago
BRCA1-associated protein 1 (BAP1) has emerged as a major tumor suppressor gene in diverse cancer types, notably in malignant pleural mesothelioma (DPM), and has also been identified as a germline cancer predisposition gene for DPM and other select cancers. However, its role in the response to DNA damage has remained unclear. Here, we show that BAP1 inactivation is associated with increased DNA…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
This study suggests that cells need to inactivate mTOR to survive nutrient stress, which could explain the rarity of mTOR mutations and the limited clinical activity of mTOR inhibitors in cancer.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1MSK Research Highlights September 29, 2023 - 7 month(s) ago
New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.
Source: www.mskcc.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Please wait whilst we redirect you - 11 month(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
A non-covalent inhibitor that binds preferentially to the inactive state of KRAS while sparing NRAS and HRAS is reported, indicating that most KRAS oncoproteins cycle between an active state and an inactive state in cancer cells.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 11How thought itself can drive tumour growth - 1 year(s) ago
How tumour–neuron interactions affect cognition and survival times.
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 12Lung adenocarcinoma promotion by air pollutants - Nature - 1 year(s) ago
Combination of epidemiology, preclinical models and ultradeep DNA profiling of clinical cohorts unpicks the inflammatory mechanism by which air pollution promotes lung cancer
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Evaluation of suspected myeloid neoplasms involves testing for recurrent, diagnostically and therapeutically relevant genetic alterations. Current molecular testing requires multiple technologies, different domains of expertise, and unconnected workflows, resulting in variable, lengthy turnaround times that can delay treatment. To address this unmet clinical need, we evaluated the Oncomine…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations - PubMed - 1 year(s) ago
Traditional genetic testing for patients with gastrointestinal stromal tumors (GISTs) focus on those with syndromic features. To assess whether expanded genetic testing of GIST patients could identify hereditary cancer predisposition, we analyzed matched tumor-germline sequencing results from 103 pa …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
RT @JCOPO_ASCO: Association of RNF43 genetic alterations with BRAFV600E and MSIhigh in #ColorectalCancer ➡️ https://t.co/j8LpRbVBP5 #CRCSM…